Library / Laws / 117th Congress / House Bills / H.R. 2853
H.R. 2853
To amend the Federal Food, Drug, and Cosmetic Act, with respect to eligibility for approval of a subsequent generic drug, to remove the barrier to that approval posed by the 180-day exclusivity period afforded to a first generic applicant that has not yet received final approval, and for other purposes.
| Print stage | Date | Size | ⠃ |
|---|---|---|---|
| Introduced in House | 2021-04-26 | 2.2K | ⠃⠗⠋ |